文献速递外周动脉疾病

美国重症肢体缺血治疗中药物洗脱支架与裸金属支架的费用比较

Comparison of the Cost of Drug-Eluting Stents versus Bare Metal Stents in the Treatment of Critical Limb Ischemia in the United States.
PubMed 文献 · Ann Vasc Surg · 2018-08-06

基于Premier数据库(2009-2015年)纳入20702例接受外周动脉血运重建的重症肢体缺血患者,其中裸金属支架组18924例(91.41%)、药物洗脱支架组1778例(8.6%)。调整混杂因素后,药物洗脱支架较裸金属支架的住院费用高407美元(95%CI 17至798,P=0.04),并观察到地区间费用差异。作者结论认为药物洗脱支架费用显著更高,需进一步研究其长期耐久性与费用。

要点

  • 重症肢体缺血患者中,药物洗脱支架组调整后住院费用较裸金属支架组高407美元(95%CI 17至798,P=0.04)。
  • 研究期间药物洗脱支架使用比例显著增加、裸金属支架相应减少(P<0.001)。
  • 教学医院费用高672美元,农村地区高1153美元,各地区均高于中西部。

核心结论

  • 在控制潜在混杂因素后,重症肢体缺血患者接受药物洗脱支架的血运重建费用显著高于裸金属支架,并观察到费用存在地区差异。
  • 作者指出需要进一步研究比较药物洗脱支架与裸金属支架的长期耐久性和费用。

研究设计与样本

  • 利用Premier数据库(2009-2015年)识别所有接受药物洗脱支架和裸金属支架的重症肢体缺血患者。
  • 采用多变量广义线性模型分析住院费用,并调整患者特征、合并症和地区特征。
  • 共纳入20702例重症肢体缺血患者,其中裸金属支架组18924例(91.41%)、药物洗脱支架组1778例(8.6%)。

主要发现

  • 裸金属支架组与药物洗脱支架组的中位总住院费用相似:裸金属支架组13342美元(8574至21166),药物洗脱支架组13243美元(8560至20232),P=0.76。
  • 调整潜在混杂因素后,药物洗脱支架较裸金属支架的费用高407美元(调整后平均差异95%CI 17至798,P=0.04)。
  • 教学医院费用较非教学医院高672美元;农村地区费用较非农村地区高1153美元。
  • 与中西部相比,南部费用高293美元(95%CI 31至555)、东北部高2006美元(95%CI 1517至2495)、西部高3312美元(95%CI 2930至3695),均P<0.05。
  • 研究期间接受药物洗脱支架的患者比例显著增加、接受裸金属支架的比例相应减少(P<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需要进一步研究比较药物洗脱支架与裸金属支架的长期耐久性和费用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite significant technical advancement in the last decade, the durability of endovascular management of critical limb ischemia (CLI) remains highly debatable. Drug-eluting stents (DESs) are being popularized for the management of CLI after its precedent success in coronary intervention. Initial reports on the durability of DES are promising. However, little is known on the additional cost of this relatively newer technology. The aim of this study is to compare the cost of the traditional bare metal stents (BMSs) to the newly introduced DES in a large cohort of CLI patients. METHODS: Using the Premier database (2009-2015), we identified all patients with CLI undergoing DES and BMS. A multivariable generalized linear model was implemented to examine in-hospital cost adjusting for patients' characteristics, comorbidities, and regional characteristics. RESULTS: A total of 20,702 patients with CLI underwent peripheral artery revascularization using BMS (18,924 [91.41%]) or DES (1,778 [8.6%]). Majority of patients were males (53%) and whites (71%). Patients undergoing BMS were slightly younger (median age [interquartile range]: 70 [62-79] versus 71 [63-80]) and were more likely to be smokers (46% vs. 39%) and have a history of cerebrovascular disease (10% vs. 8%) and chronic pulmonary disease (24.5% vs. 20.9%) as compared with those undergoing DES (all P < 0.05). On the other hand, DES patients had a high prevalence of diabetes (4% vs. 3%) and renal disease (25% vs. 22%) (both P < 0.05). There was also a significant increase in the proportion of patients undergoing DES and a corresponding decrease in BMS (P < 0.001) over the study period. Median total in-hospitalization cost (BMS: $13,342 [8,574 to 21,166], DES: $13,243 [8,560-20,232], P = 0.76) was similar for both approaches. After adjusting for potential confounders, DES was associated with $407 higher cost than BMS (adjusted mean difference [95% confidence interval]: 407 [17 to 798], P = 0.04). In addition, the cost was $672 higher in teaching hospitals, $1,153 higher in Rural areas, and increased in all regions compared with the Midwest (adjusted mean difference [95% confidence interval]-South: $293 [31 to 555], Northeast: $2,006 [1,517 to 2,495], West: $3,312 [2,930 to 3,695], all P < 0.05). CONCLUSIONS: In this large cohort of CLI patients, after controlling for potential confounders, we demonstrated that the cost of endovascular revascularization is significantly higher in patients undergoing DES than those undergoing BMS. Regional disparities in cost were also observed. Further studies looking at the long-term durability and costs of DES versus BMS are needed.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Locham SS, Paracha N, Dakour-Aridi H, et al. Comparison of the Cost of Drug-Eluting Stents versus Bare Metal Stents in the Treatment of Critical Limb Ischemia in the United States. Ann Vasc Surg. 2018. PMID: 30092444. doi:10.1016/j.avsg.2018.05.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。